Press Releases

The primary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) with either advanced cirrhosis...

Submission based on positive results of the landmark, global Phase 3 study, CheckMate -057 evaluating overall survival versus standard of care in non-squamous non-small cell lung cancer patients U.S. FDA grants application priority review, and Opdivo Breakthrough Therapy Designation...

Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Tuesday, September 8 at 8 a.m. EDT (6 a.m. MDT) to review data presented at the 16th Annual World Conference on Lung Cancer (WCLC) in Denver, CO. ...

Coramaze technologies GmbH, a German medical device company, is developing themitramaze® valve repair system – a novel concept for transcatheter mitral valve repair (TMVRep) intended for treatment of inoperable patients suffering from severe functional mitral regurgitation (fMR). ...

 "PRM-151 will complement our growing early-stage fibrosis portfolio, and we are excited by its potential to address multiple fibrotic diseases." Bristol-Myers Squibb Company (NYSE:BMY) and Promedior, Inc. announced the companies have entered into an agreement that...

 "We are excited to work with QIMR Berghofer Medical Research Institute, a partner that brings significant experience and expertise in cancer research." Bristol-Myers Squibb Company (NYSE:BMY) and QIMR Berghofer Medical Research Institute have signed a research...

This acceptance for review marks the first in the U.S. for a SLAMF7-directed immunostimulatory antibody   "AbbVie is encouraged by the FDA’s decision to award priority review to this application" Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie...